-
公开(公告)号:US5268453A
公开(公告)日:1993-12-07
申请号:US918953
申请日:1992-07-30
申请人: Robin J. Andy , Eric R. Larson
发明人: Robin J. Andy , Eric R. Larson
CPC分类号: C07K14/62 , A61K38/00 , Y10S514/866
摘要: Human insulin analogs are disclosed. These analogs are tissue-selective. Accordingly, pharmaceutical formulations containing the analogs of the invention provide superior clinical benefits as compared to human insulin when used in the treatment of patients suffering from diabetes. The analogs are modified at amino residue A12, A15 or A19, are different from the naturally occurring residue at said position, and are hepatoselective. Also disclosed are human insulin analogs modified at amino acid residues A12 or A14 or amino acid residues A10 and A13 different from naturally occurring residues or residues at said position or positions and are peripheral selective. DNA sequences and microorganisms comprising sequences coding for human insulin analogs are also provided. Processes for preparing the human insulin analogs are described.
摘要翻译: 人胰岛素类似物被公开。 这些类似物是组织选择性的。 因此,当用于治疗患有糖尿病的患者时,与人胰岛素相比,含有本发明类似物的药物制剂提供了优异的临床益处。 类似物在氨基残基A12,A15或A19处被修饰,与所述位置处的天然存在的残基不同,并且是肝选择性的。 还公开了在氨基酸残基A12或A14处修饰的人胰岛素类似物或在所述位置或位置处与天然存在的残基或残基不同的氨基酸残基A10和A13,并且是周边选择性的。 还提供了包含编码人胰岛素类似物的序列的DNA序列和微生物。 描述了制备人胰岛素类似物的方法。
-
2.
公开(公告)号:US20240350608A1
公开(公告)日:2024-10-24
申请号:US18634326
申请日:2024-04-12
申请人: Pfizer Inc.
发明人: Bishwa Raj Bhetuwal , Kaushik Dutta , Jianxin Gu , Sunayana Kapil , Jin-Hwan Kim , Justin Keith Moran , Suddham Singh , YuYing Yang
IPC分类号: A61K39/09 , A61K39/00 , A61K39/385 , A61K47/64
CPC分类号: A61K39/092 , A61K47/646 , A61K39/385 , A61K2039/55516
摘要: The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic compositions and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.
-
3.
公开(公告)号:US20240325515A1
公开(公告)日:2024-10-03
申请号:US18621962
申请日:2024-03-29
申请人: Pfizer Inc.
发明人: Kaushik Dutta , Caitlyn Gallagher , Isis Kanevsky , Jin-hwan Kim , Justin Keith Moran , Suddham Singh , Abhishek Ravindra Vartak
CPC分类号: A61K39/092 , A61K47/42 , A61P31/04 , A61K2039/55505
摘要: The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates), kits comprising said immunogenic compositions and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.
-
公开(公告)号:US20240252614A1
公开(公告)日:2024-08-01
申请号:US18413734
申请日:2024-01-16
申请人: Pfizer Inc.
发明人: Damon Andrew Hollands Berman , Ye Che , Alexey Vyacheslavovitch Gribenko , Bridget Yih Jiin Huang , Weiqiang Li , Yan Li , Kena Anne Swanson , Helen Chen Wang , Sabine Susanne Wellnitz , Kam Ho Wong , Qi Yang , Aiping Zhu
IPC分类号: A61K39/155 , A61K9/51 , A61K39/00 , A61K39/12 , C07K14/005 , C07K16/10
CPC分类号: A61K39/155 , A61K9/5123 , A61K39/12 , C07K14/005 , C07K16/10 , A61K2039/70
摘要: The present disclosure relates to hMPV F, PIV3 F and PIV1 F protein mutants, nucleic acids or vectors encoding a hMPV F, PIV3 F and PIV1 F protein mutant, compositions comprising a hMPV F, PIV3 F and PIV1 F protein mutant or nucleic acid, and uses of the hMPV F, PIV3 F and PIV1 F protein mutants, nucleic acids or vectors, and compositions.
-
公开(公告)号:US12036203B2
公开(公告)日:2024-07-16
申请号:US16597894
申请日:2019-10-10
IPC分类号: A61K31/357 , A61K31/155 , A61K31/4985 , A61K31/7048 , A61P9/04 , A61P9/10
CPC分类号: A61K31/357 , A61K31/155 , A61K31/4985 , A61K31/7048 , A61P9/04 , A61P9/10 , A61K31/4985 , A61K2300/00 , A61K31/7048 , A61K2300/00 , A61K31/155 , A61K2300/00
摘要: The present invention relates to the use of certain SGLT-2 inhibitors, such as ertugliflozin or a pharmaceutically acceptable salt or a co-crystal thereof, for treating, reducing the risk of and/or preventing heart failure, myocardial infarction, cardiovascular disease or cardiovascular death in animals without type 2 or type 1 diabetes mellitus, or in animals with pre-diabetes, or in animals with type 2 or type 1 diabetes mellitus or pre-diabetes.
-
公开(公告)号:US20240208894A1
公开(公告)日:2024-06-27
申请号:US18551619
申请日:2022-04-06
申请人: Pfizer Inc.
IPC分类号: C07C229/46 , C07C67/29 , C07C227/08 , C07C229/24
CPC分类号: C07C229/46 , C07C67/29 , C07C227/08 , C07C229/24
摘要: The present disclosure provides methods for producing a compound having a chemical formula of Formula I, wherein R3 and R2 are independently a i) linear or branched or cyclic, ii) saturated or unsaturated, and iii) substituted or unsubstituted hydrocarbon group comprising 1 to 30 carbon atoms; R3 is a i′) lincar or branched or cyclic. ii′) saturated or unsaturated, and iii′) substituted or unsubstituted hydrocarbon group: and L1, L2 and L3 independently are linkers.
-
7.
公开(公告)号:US20240189410A1
公开(公告)日:2024-06-13
申请号:US18535116
申请日:2023-12-11
申请人: Pfizer Inc.
发明人: Annaliesa Sybil Anderson , Marina A. Gonzalez-Garis , Lei Hu , Isis Kanevsky , Paul Arthur Liberator , Justin Keith Moran , Lynn Marie Phelan , Michael William Pride , Shuai Shi , Naveen Surendran
CPC分类号: A61K39/08 , A61K39/39 , A61P31/04 , A61K2039/55561
摘要: The present invention relates to immunogenic compositions that comprise a Clostridioides difficile toxoid A and/or a C. difficile toxoid B, and an adjuvant, and methods of use thereof. The present invention further relate to a methods for eliciting an enhanced immune response in a human against a C. difficile infection. The methods include administering to the human an effective dose of an immunogenic composition, which includes a C. difficile toxoid and an adjuvant, wherein the composition is administered two times.
-
公开(公告)号:US11993625B2
公开(公告)日:2024-05-28
申请号:US16477290
申请日:2018-01-10
申请人: PFIZER INC.
发明人: Omar Khaled Ahmad , Stephen Paul Brown , Kenneth John Dirico , Russell Dushin , Gary Frederick Filzen , Sujiet Puthenveetil , Pavel Strop , Chakrapani Subramanyam , Lawrence N. Tumey
CPC分类号: C07H15/26 , A61K47/6807 , A61P35/00 , A61K45/06
摘要: The present invention is directed to novel calicheamicin derivatives useful as payloads in antibody-drug-conjugates (ADC's), and to payload-linker compounds and ADC compounds comprising the same; to pharmaceutical compositions comprising the same and to methods for using the same to treat pathological conditions such as cancer.
-
公开(公告)号:US20240156977A1
公开(公告)日:2024-05-16
申请号:US18492348
申请日:2023-10-23
申请人: Pfizer Inc.
发明人: Andrea Therese HOOPER , Kimberly Ann MARQUETTE , Chakrapani SUBRAMANYAM , Hans-Peter GERBER , Chad Michael MAY
CPC分类号: A61K47/6803 , A61K47/6843 , A61P35/00 , C07K16/18 , A61K38/08 , A61K47/6811
摘要: The present invention provides antibodies and antibody-drug conjugates that bind to the extra domain B splice variant of fibronectin 1 and methods for preparing and using the same.
-
公开(公告)号:US11980669B2
公开(公告)日:2024-05-14
申请号:US16807375
申请日:2020-03-03
申请人: PFIZER INC.
发明人: Xiaotian Zhong , Amarnauth Shastrie Prashad , Ronald William Kriz , Tao He , Will Somers , Wenge Wang , Leo Joseph Letendre
CPC分类号: A61K47/6889 , A61K38/05 , A61K47/68 , A61K47/6817 , A61K47/6851 , A61K47/6855 , C07K16/00 , C07K16/30 , C07K2317/14 , C07K2317/40 , C07K2317/526 , C07K2317/55 , C07K2317/94
摘要: An antibody production process in mammalian cells in which engineered unpaired cysteine residues are post-translationally modified and capped with particular chemical entities, which capped antibodies are well suited to further site-specific conjugation steps to form antibody-drug conjugates (ADCs) or protein drug conjugates; ADCs produced using these capped antibodies including in particular ADCs formed by the selective reduction of the capped antibodies' cysteine residues, and ADCs formed using chemical handles such as aldehyde/azide/alkyne biorthogonal groups, which permit additional drug conjugation chemistry; and uncapped antibodies produced by cells in low cysteine, cysteine and glutathione media, and ADCs produced via direct conjugation to these uncapped antibodies.
-
-
-
-
-
-
-
-
-